Exact Sciences/$EXAS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Exact Sciences
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.
Ticker
$EXAS
Sector
Primary listing
Employees
6,950
Headquarters
Website
Exact Sciences Metrics
BasicAdvanced
$10B
-
-$5.40
1.05
-
Price and volume
Market cap
$10B
Beta
1.05
52-week high
$70.35
52-week low
$38.81
Average daily volume
3.7M
Financial strength
Current ratio
2.889
Quick ratio
2.384
Long term debt to equity
101.215
Total debt to equity
102.731
Interest coverage (TTM)
-3.85%
Profitability
EBITDA (TTM)
67.114
Gross margin (TTM)
69.63%
Net profit margin (TTM)
-34.19%
Operating margin (TTM)
-4.73%
Effective tax rate (TTM)
0.91%
Revenue per employee (TTM)
$420,000
Management effectiveness
Return on assets (TTM)
-1.39%
Return on equity (TTM)
-35.51%
Valuation
Price to revenue (TTM)
3.413
Price to book
4.12
Price to tangible book (TTM)
-11.78
Price to free cash flow (TTM)
59.154
Free cash flow yield (TTM)
1.69%
Free cash flow per share (TTM)
0.91
Growth
Revenue change (TTM)
12.56%
Earnings per share change (TTM)
461.44%
3-year revenue growth (CAGR)
14.89%
10-year revenue growth (CAGR)
70.83%
3-year earnings per share growth (CAGR)
8.48%
10-year earnings per share growth (CAGR)
12.83%
What the Analysts think about Exact Sciences
Analyst ratings (Buy, Hold, Sell) for Exact Sciences stock.
Bulls say / Bears say
Exact Sciences reported record Q2 2025 revenue of $811 million, up 16% year-over-year, beating consensus estimates and raising full-year guidance by $55 million, demonstrating strong commercial performance and test adoption. (Nasdaq)
The exclusive licensing agreement with Freenome for blood-based colorectal cancer screening technology fast-tracks Exact Sciences’ entry into this market, strengthening its position against new MCED competitors. (Investor’s Business Daily)
New contracts with major insurers like Humana and Centene bring Cologuard Plus in-network for around 40 million members, expanding access and supporting ongoing revenue growth from screening. (Finviz)
Gross margin shrank by 49 basis points in Q2 as cost of revenues and operating expenses jumped 17.9%, with sales & marketing up 16.8% and G&A up 17.5%, which could pressure future profitability. (Zacks)
Exact Sciences’ stock dropped 8% after the $75 million licensing deal with Freenome, as analysts questioned both the high upfront payment and the company’s record for M&A returns—potentially signaling a misstep in its defensive strategy. (Investor’s Business Daily)
Management warned that reimbursement and inclusion in guidelines for the upcoming multi-cancer Cancerguard test will happen gradually, posing a risk to near-term revenue growth and test adoption. (Finviz)
Data summarised monthly by Lightyear AI. Last updated on 8 Sept 2025.
Exact Sciences Financial Performance
Revenues and expenses
Exact Sciences Earnings Performance
Company profitability
Exact Sciences News
AllArticlesVideos
Legal Win for Geneoscopy as Exact Sciences Withdraws Preliminary Injunction Against ColoSense®
Business Wire2 weeks ago
Exact Sciences to Participate in September Investor Conferences
Business Wire3 weeks ago
Exact Sciences Dip A Chance To Buy As Freenome Deal Fortifies Future: Analyst
Benzinga1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Exact Sciences stock?
Exact Sciences (EXAS) has a market cap of $10B as of September 08, 2025.
What is the P/E ratio for Exact Sciences stock?
The price to earnings (P/E) ratio for Exact Sciences (EXAS) stock is 0 as of September 08, 2025.
Does Exact Sciences stock pay dividends?
No, Exact Sciences (EXAS) stock does not pay dividends to its shareholders as of September 08, 2025.
When is the next Exact Sciences dividend payment date?
Exact Sciences (EXAS) stock does not pay dividends to its shareholders.
What is the beta indicator for Exact Sciences?
Exact Sciences (EXAS) has a beta rating of 1.05. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.